Benjamin T Crane1,2,3, Michael C Schubert4,5. 1. Department of Otolaryngology, University of Rochester, Rochester, New York. 2. Department of Neuroscience, University of Rochester, Rochester, New York. 3. Department of Bioengineering, University of Rochester, Rochester, New York. 4. Department of Otolaryngology, Johns Hopkins University, Baltimore, Maryland, U.S.A. 5. Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, Maryland, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: There is a large variation in vestibular rehabilitation (VR) results depending on type of therapy, adherence, and the appropriateness for the patient's level of function. A novel adaptive vestibular rehabilitation (AVR) program was developed and evaluated. STUDY DESIGN: Technology and procedure development, and prospective multicenter trial. METHODS: Those with complete unilateral vestibular hypofunction and symptomatic at least 3 months with a Dizziness Handicap Inventory (DHI) >30 were eligible. Patients were given a device to use with their own computer. They were instructed to use the program daily, with each session lasting about 10 minutes. The task consisted of reporting orientation of the letter C, which appeared when their angular head velocity exceeded a threshold. The letter size and head velocity required were adjusted based on prior performance. Performance on the task was remotely collected by the investigator as well as a weekly DHI score. RESULTS: Four patients aged 31 to 74 years (mean = 51 years) were enrolled in this feasibility study to demonstrate efficacy. Two had treated vestibular schwannomas and two had vestibular neuritis. Starting DHI was 32 to 56 (mean = 42), which was reduced to 0 to 16 (mean = 11.5) after a month of therapy, a clinically and statistically significant (P < .05) improvement. The three who continued therapy an additional month improved to a DHI of 4. CONCLUSIONS: This AVR method has advantages over traditional VR in terms of cost and customization for patient ability and obtained a major improvement in symptoms. This study demonstrated a clinically and statistically significant decrease in symptoms after 4 weeks of therapy. LEVEL OF EVIDENCE: 2b. Laryngoscope, 128:713-718, 2018.
OBJECTIVES/HYPOTHESIS: There is a large variation in vestibular rehabilitation (VR) results depending on type of therapy, adherence, and the appropriateness for the patient's level of function. A novel adaptive vestibular rehabilitation (AVR) program was developed and evaluated. STUDY DESIGN: Technology and procedure development, and prospective multicenter trial. METHODS: Those with complete unilateral vestibular hypofunction and symptomatic at least 3 months with a Dizziness Handicap Inventory (DHI) >30 were eligible. Patients were given a device to use with their own computer. They were instructed to use the program daily, with each session lasting about 10 minutes. The task consisted of reporting orientation of the letter C, which appeared when their angular head velocity exceeded a threshold. The letter size and head velocity required were adjusted based on prior performance. Performance on the task was remotely collected by the investigator as well as a weekly DHI score. RESULTS: Four patients aged 31 to 74 years (mean = 51 years) were enrolled in this feasibility study to demonstrate efficacy. Two had treated vestibular schwannomas and two had vestibular neuritis. Starting DHI was 32 to 56 (mean = 42), which was reduced to 0 to 16 (mean = 11.5) after a month of therapy, a clinically and statistically significant (P < .05) improvement. The three who continued therapy an additional month improved to a DHI of 4. CONCLUSIONS: This AVR method has advantages over traditional VR in terms of cost and customization for patient ability and obtained a major improvement in symptoms. This study demonstrated a clinically and statistically significant decrease in symptoms after 4 weeks of therapy. LEVEL OF EVIDENCE: 2b. Laryngoscope, 128:713-718, 2018.
Authors: Courtney D Hall; Susan J Herdman; Susan L Whitney; Stephen P Cass; Richard A Clendaniel; Terry D Fife; Joseph M Furman; Thomas S D Getchius; Joel A Goebel; Neil T Shepard; Sheelah N Woodhouse Journal: J Neurol Phys Ther Date: 2016-04 Impact factor: 3.649